Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients

Launched by MAYO CLINIC · May 16, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on improving diabetes management for patients who are receiving care at home through the Mayo Clinic's Advanced Care at Home Program. The study aims to compare how well continuous glucose monitors (CGMs) help control blood sugar levels when paired with diabetes education versus the standard method of checking blood sugar using glucometers (a device that pricks the finger). Participants in this trial will be individuals aged 65 to 74 who have been diagnosed with either type 1 or type 2 diabetes and are using insulin for their treatment.

To participate, patients must be admitted to the Advanced Care at Home Program for at least 72 hours and be able to give consent. However, certain individuals are not eligible, such as those currently experiencing severe diabetes complications or those using a CGM already. If eligible, participants can expect to receive diabetes education and learn how to use a CGM, which continuously tracks blood sugar levels, potentially leading to better diabetes control. This trial is currently recruiting participants, and it offers a chance to explore new ways to manage diabetes more effectively while receiving care at home.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are admitted to Advanced Care at Home (ACH) Program and supposed to remain in ACH for at least 72 hours.
• • Patients with previous diagnosis of DM type 1 or type 2.
• • Patients taking subcutaneous (SQ) insulin either via multidose injections or SQ insulin pump.
• • Capable of giving signed informed consent
• Exclusion Criteria:
• • Actively treated for diabetes ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS).
• • Participants taking acetaminophen more than 4g per day or more than 1gm every 6 hours.
• • Participants with altered mental status.
• • Participants diagnosed with dementia.
• • Patients with suicidal ideations or experiencing suicidal behavior.
• • Patients with liver cirrhosis.
• • Patients with End Stage Renal Disease on dialysis bot hemodialysis or peritoneal dialysis.
• • Participants with allergy to medical grade adhesive or medical tape.
• • Participants taking hydroxyurea.
• • Participants who are pregnant, wanting to become pregnant, or nursing during study period.
• • Patients with a planned MRI within the following 10 days after admission to ACH.
• • Participants currently using continuous glucose monitor (CGM) to dose insulin or check glucose level.
• • Participants with diabetes mellitus (DM) treated with diet alone.
• • Participants with DM treated with oral hypoglycemic medications.
• • Participants with DM treated with one SQ insulin injection daily.
• • Participants enrolled in other studies addressing CGM use.
• • Participants physically or emotionally incapable of handling a cell phone with a smart display.
• • Participants with hearing impaired to a degree that they are not able to hear a smart phone alert or alarm.
• • Patients lacking WIFI or Cellular coverage needed to connect the monitoring cell phone to Internet network.